Literature DB >> 28830270

Quality assessment of positron emission tomography scans: recommendations for future multicentre trials.

Evelyn E C de Jong1, Wouter van Elmpt1, Otto S Hoekstra2, Harry J M Groen3, Egbert F Smit4,5, Ronald Boellaard6, Philippe Lambin1, Anne-Marie C Dingemans7.   

Abstract

BACKGROUND: Standardization protocols and guidelines for positron emission tomography (PET) in multicenter trials are available, despite a large variability in image acquisition and reconstruction parameters exist. In this study, we investigated the compliance of PET scans to the guidelines of the European Association of Nuclear Medicine (EANM). From these results, we provide recommendations for future multicenter studies using PET.
MATERIAL AND METHODS: Patients included in a multicenter randomized phase II study had repeated PET scans for early response assessment. Relevant acquisition and reconstruction parameters were extracted from the digital imaging and communications in medicine (DICOM) header of the images. The PET image parameters were compared to the guidelines of the EANM for tumor imaging version 1.0 recommended parameters.
RESULTS: From the 223 included patients, 167 baseline scans and 118 response scans were available from 15 hospitals. Scans of 19% of the patients had an uptake time that fulfilled the Uniform Protocols for Imaging in Clinical Trials response assessment criteria. The average quality score over all hospitals was 69%. Scans with a non-compliant uptake time had a larger standard deviation of the mean standardized uptake value (SUVmean) of the liver than scans with compliant uptake times.
CONCLUSIONS: Although a standardization protocol was agreed on, there was a large variability in imaging parameters. For future, multicenter studies including PET imaging a prospective central quality review during patient inclusion is needed to improve compliance with image standardization protocols as defined by EANM.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28830270     DOI: 10.1080/0284186X.2017.1346824

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  5 in total

1.  An account of data entry inconsistencies and their impact on positron emission tomography quantification.

Authors:  Tram Nguyen; Christina Baun; Poul Flemming Høilund-Carlsen
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

2.  Challenges and caveats of a multi-center retrospective radiomics study: an example of early treatment response assessment for NSCLC patients using FDG-PET/CT radiomics.

Authors:  Janna E van Timmeren; Sara Carvalho; Ralph T H Leijenaar; Esther G C Troost; Wouter van Elmpt; Dirk de Ruysscher; Jean-Pierre Muratet; Fabrice Denis; Tanja Schimek-Jasch; Ursula Nestle; Arthur Jochems; Henry C Woodruff; Cary Oberije; Philippe Lambin
Journal:  PLoS One       Date:  2019-06-03       Impact factor: 3.240

Review 3.  Simultaneous PET/MRI: The future gold standard for characterizing motor neuron disease-A clinico-radiological and neuroscientific perspective.

Authors:  Freimut D Juengling; Frank Wuest; Sanjay Kalra; Federica Agosta; Ralf Schirrmacher; Alexander Thiel; Wolfgang Thaiss; Hans-Peter Müller; Jan Kassubek
Journal:  Front Neurol       Date:  2022-08-17       Impact factor: 4.086

4.  Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial.

Authors:  Relinde I Y Lieverse; Evert J Van Limbergen; Cary J G Oberije; Esther G C Troost; Sine R Hadrup; Anne-Marie C Dingemans; Lizza E L Hendriks; Franziska Eckert; Crispin Hiley; Christophe Dooms; Yolande Lievens; Monique C de Jong; Johan Bussink; Xavier Geets; Vincenzo Valentini; Giuliano Elia; Dario Neri; Charlotte Billiet; Amir Abdollahi; David Pasquier; Pierre Boisselier; Ala Yaromina; Dirk De Ruysscher; Ludwig J Dubois; Philippe Lambin
Journal:  BMC Cancer       Date:  2020-06-15       Impact factor: 4.430

5.  Robust, independent and relevant prognostic 18F-fluorodeoxyglucose positron emission tomography radiomics features in non-small cell lung cancer: Are there any?

Authors:  Tom Konert; Sarah Everitt; Matthew D La Fontaine; Jeroen B van de Kamer; Michael P MacManus; Wouter V Vogel; Jason Callahan; Jan-Jakob Sonke
Journal:  PLoS One       Date:  2020-02-25       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.